statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN  Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 290,500...

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Short Interest Update

SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...

Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aslan Pharmaceuticals (ASLN Research Report), Urogen Pharma...

Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aslan Pharmaceuticals price target lowered by $8 at H.C. Wainwright, here's why

Aslan Pharmaceuticals price target lowered by $5 at Piper Sandler, here's why

Aslan Pharmaceuticals announces $5M registered direct offering

SAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative...

ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering

TREK-DX, the first randomized, double-blind, placebo-controlled study to be conducted in a dupilumab-experienced atopic dermatitis (AD) patient population, has started enrolling patients in the US...

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and...

ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN  Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 15th, there was short interest...

Short Interest in ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Drops By 46.7%

Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which develops novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Volume	319,651.00
52-Wk High	$4.69
52-Wk Low	$0.392

ASLN ASLAN Pharmaceuticals

About

Feed

News

Fundamentals